GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b.i.d.). To summarize current knowledge about GLP-1 receptor agonist. At present, GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide). A daily oral preparation of semaglutide, which has demonstrated clinical effectiveness close to the once-weekly…

• EL
  Eli Lilly and Company
• A
  AstraZeneca
• BI
  Boehringer Ingelheim
• MK
  Merck KGaA
• DF
  Deutsche Forschungsgemeinschaft
• NN
  Novo Nordisk
• SD
  Sanofi-Aventis Deutschland